Phase 1/2 trial of Mogamulizumab and Opdivo in advanced solid tumours announced
30 July 2015 | By Victoria White
Kyowa Hakko Kirin and Bristol-Myers Squibb are to conduct a Phase 1/2 combination study with mogamulizumab and Opdivo in advanced solid tumours...